Scarica l'app Stockscreener
0.8567
4.93%
-0.0444
Dopo l'orario di chiusura:
.90
0.0433
+5.05%
Precedente Chiudi:
$0.9011
Aprire:
$0.9401
Volume 24 ore:
20.73M
Relative Volume:
5.92
Capitalizzazione di mercato:
$154.28M
Reddito:
$850.00K
Utile/perdita netta:
$-68.17M
Rapporto P/E:
-2.0814
EPS:
-0.4116
Flusso di cassa netto:
$-53.29M
1 W Prestazione:
-24.19%
1M Prestazione:
-64.74%
6M Prestazione:
-84.28%
1 anno Prestazione:
-75.31%
Intervallo 1D:
$0.8294
$0.9798
Intervallo di 1 settimana:
$0.8294
$1.15
Portata 52W:
$0.8294
$6.88
Compass Therapeutics Inc Stock (CMPX) Company Profile
Nome
Compass Therapeutics Inc
Settore
Industria
Telefono
617-500-8099
Indirizzo
80 GUEST STREET, BOSTON
Compare CMPX vs VRTX, MRNA, REGN, ARGX, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CMPX
Compass Therapeutics Inc
|
0.8567 | 203.50M | 850.00K | -68.17M | -53.29M | -0.4116 |
VRTX
Vertex Pharmaceuticals Inc
|
504.73 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
190.01 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
735.20 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.21 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
206.64 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Compass Therapeutics Inc Stock (CMPX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-02-13 | Iniziato | Craig Hallum | Buy |
| 2026-01-05 | Iniziato | William Blair | Outperform |
| 2025-12-03 | Iniziato | Canaccord Genuity | Buy |
| 2025-12-03 | Iniziato | Cantor Fitzgerald | Overweight |
| 2025-12-03 | Iniziato | Citizens JMP | Mkt Outperform |
| 2025-07-01 | Ripresa | Raymond James | Outperform |
| 2025-04-02 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2025-02-24 | Iniziato | Guggenheim | Buy |
| 2025-02-19 | Iniziato | Piper Sandler | Overweight |
| 2024-12-23 | Iniziato | D. Boral Capital | Buy |
| 2024-11-15 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2024-09-16 | Aggiornamento | Ladenburg Thalmann | Neutral → Buy |
| 2023-01-31 | Iniziato | Jefferies | Buy |
| 2023-01-27 | Iniziato | Stifel | Buy |
| 2022-05-23 | Ripresa | H.C. Wainwright | Buy |
| 2022-03-15 | Iniziato | Ladenburg Thalmann | Buy |
| 2022-01-19 | Iniziato | B. Riley Securities | Buy |
| 2021-12-22 | Iniziato | Raymond James | Outperform |
| 2021-12-20 | Iniziato | SVB Leerink | Outperform |
| 2021-12-15 | Iniziato | Wedbush | Outperform |
Mostra tutto
Compass Therapeutics Inc Borsa (CMPX) Ultime notizie
Compass Therapeutics CAO Neil Lerner buys $2,849 in CMPX shares By Investing.com - Investing.com Nigeria
Compass Therapeutics (CMPX) Insider Buy: Chief Accounting Officer Neil Lerner Purchases 2,500 Shares - GuruFocus
Form 4 Compass Therapeutics, Inc. For: 25 September By Investing.com - Investing.com Nigeria
Is Compass Therapeutics, Inc. (CMPX) the Healthcare Stocks Stock Everyone's About to Talk About? - kalkinemedia.com
Compass Therapeutics CAO Neil Lerner buys $2,849 in CMPX shares - Investing.com
After buying 2,500 shares, Compass Therapeutics (CMPX) accounting chief reports a 400,000-share position - Stock Titan
How Does FDA Feedback Change the Tovecimig Path for Compass Therapeutics (NASDAQ:CMPX)? - Kalkine Media
Compass Therapeutics (CMPX) Short Interest & Short Float | Updated Sep 2026 - MarketBeat
Compass Therapeutics Is Maintained at Market Outperform by Citizens - Moomoo
Compass Therapeutics Shares Drop After Downgrade From Wedbush - marketscreener.com
Compass Therapeutics, Inc. (CMPX) Stock Price, News, Quote & History - Yahoo! Finance Canada
Compass Therapeutics stock downgraded at Wedbush (CMPX:NASDAQ) - Seeking Alpha
Compass Therapeutics' tovecimig fails to improve survival in biliary tract cancer, but BLA submission planned. - Pluang
Compass Therapeutics: A Promising, But Shrinking, Window Of Opportunity (NASDAQ:CMPX) - Seeking Alpha
Compass Therapeutics’ FDA Setback Raises Concerns On Wall Street — H.C. Wainwright Calls Tovecimig Filing Strategy ‘Risky’ - Stocktwits
This Autoliv Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday - Benzinga
Citizens maintains Market Outperform rating on Compass Therapeutics, $4 price target - TradingView
Guggenheim maintains Buy rating on Compass Therapeutics, $4 price target - TradingView
Wedbush Downgrades Compass Therapeutics to Neutral From Outperform, Cuts Price Target to $1 From $5 - marketscreener.com
Wedbush downgrades Compass Therapeutics to Neutral, sets price target to $1 - TradingView
Cantor Fitzgerald reiterates Compass Therapeutics stock rating By Investing.com - Investing.com Canada
H.C. Wainwright cuts Compass Therapeutics stock price target on FDA trial recommendation - Investing.com Canada
Guggenheim cuts Compass Therapeutics stock price target on FDA trial requirement - Investing.com
HC Wainwright & Co. maintains Buy rating on Compass Therapeutics, $12 price target - TradingView
Citizens cuts Compass Therapeutics stock price target on FDA trial request - Investing.com Canada
COMPASS THERAPEUTICS INC. : WEDBUSH CUTS TO NEUTRAL FROM OUTPERFORM; CUTS TARGET PRICE TO $1 FROM $5 - Bitget
CMPX Plunge Wipes Out $104M After FDA Demands Fresh Trial For Cancer Drug — Wedbush Sees Another 19% Downside - Stocktwits
Compass Therapeutics Downgraded, Shares Plunge 32% After FDA Feedback - intellectia.ai
Wedbush downgrades Compass Therapeutics stock rating on FDA trial concerns - Investing.com Canada
Compass Therapeutics Craters, FDA Pushes Survival-Trial Demand for Cancer Drug - AOL.ca
Why Did Compass Therapeutics Stock Plunge Today?Compass Therapeutics (NASDAQ:CMPX) - benzinga.com
Compass shares fall after FDA tovecimig feedback - grafa.com
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Compass Therapeutics Provides Regulatory Update on Tovecimig in Biliary Tract Cancer Following FDA Feedback - Investing News Network
Compass Therapeutics stock price target maintained at $6 by Stifel - Investing.com Canada
Compass Therapeutics Faces FDA Pushback on Tovecimig Trial - TipRanks
Compass Therapeutics Says FDA Recommends New Tovecimig Trial in Biliary Tract Cancer; Shares Fall - marketscreener.com
Form 8K Compass Therapeutics, Inc. For: 22 September By Investing.com - Investing.com Nigeria
CMPX Stock Slides As Traders Watch Volatile Support Zone - StocksToTrade
Compass Therapeutics Provides Regulatory Update On Tovecimig In Biliary Tract Cancer Following FDA Feedback - TradingView
Form 8K Compass Therapeutics, Inc. For: 22 September - Investing.com India
Compass says FDA seeks additional trial for lead asset (CMPX) - Seeking Alpha
Compass Therapeutics says FDA recommends survival trial before BLA for tovecimig in biliary tract cancer - TradingView
Compass Therapeutics, Inc. Provides Regulatory Update On Tovecimig In Biliary Tract Cancer Following FDA Feedback - marketscreener.com
Compass Therapeutics’ CMPX Is Still Waiting On Its BLA Moment - Finimize
Compass Therapeutics Inc. (CMPX) Stock Price Target & Forecast - TradingKey
CCORF Maintains Compass Therapeutics(CMPX.US) With Buy Rating, Maintains Target Price $7 - Moomoo
Compass Therapeutics, Inc. (CMPX) Financials FY2025: Revenue $0, Net Loss $66.5M - Stock Titan
Compass Therapeutics Inc. (CMPX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Compass (CMPX) Earnings Update: The EPS Result Is Below Expectation in the Current Update; After Earnings: Shares Finish 0.21% Higher on the DayProfit Cycle Analysis - vinanet.vn
CMPX Stock Has Retail Buzzing Ahead Of High-Stakes Cancer Drug Trial Update - Stocktwits
Compass Therapeutics Inc Azioni (CMPX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Compass Therapeutics Inc Azioni (CMPX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Lerner Neil | Chief Accounting Officer |
Sep 24 '26 |
Buy |
1.14 |
2,500 |
2,850 |
400,000 |
0.05%
0.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):